0

Casein Kinase 1δ/ε Inhibitor PF-5006739 Attenuates Opioid Drug-Seeking Behavior

Travis T Wager, Ramalakshmi Y Chandrasekaran, Jenifer Bradley, David Rubitski, Helen Berke, Scot Mente, Todd Butler, Angela Doran, Cheng Chang, Katherine Fisher, John Knafels, Shenping Liu, Jeff Ohren, etc.

ACS Chem Neurosci. 2014 Dec 17;5(12):1253-65.

PMID: 25299732

Abstract:

Casein kinase 1 delta (CK1δ) and casein kinase 1 epsilon (CK1ε) inhibitors are potential therapeutic agents for a range of psychiatric disorders. The feasibility of developing a CNS kinase inhibitor has been limited by an inability to identify safe brain-penetrant compounds with high kinome selectivity. Guided by structure-based drug design, potent and selective CK1δ/ε inhibitors have now been identified that address this gap, through the design and synthesis of novel 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine derivatives. PF-5006739 (6) possesses a desirable profile, with low nanomolar in vitro potency for CK1δ/ε (IC50 = 3.9 and 17.0 nM, respectively) and high kinome selectivity. In vivo, 6 demonstrated robust centrally mediated circadian rhythm phase-delaying effects in both nocturnal and diurnal animal models. Further, 6 dose-dependently attenuated opioid drug-seeking behavior in a rodent operant reinstatement model in animals trained to self-administer fentanyl. Collectively, our data supports further development of 6 as a promising candidate to test the hypothesis of CK1δ/ε inhibition in treating multiple indications in the clinic.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP1293395671 PF-5006739 PF-5006739 1293395-67-1 Price
qrcode